Literature DB >> 29966567

Hospital-Based Study of Compliance with NCCN Guidelines and Predictive Factors of Sentinel Lymph Node Biopsy in the Setting of Thin Melanoma Using the National Cancer Database.

Sarah A Hayek1, Amanda Munoz, James T Dove, Marie Hunsinger, Tania Arora, Jeffrey Wild, Mohsen Shabahang, Joseph Blansfield.   

Abstract

Thin melanoma is the most common form of melanoma in the United States. The National Comprehensive Cancer Network (NCCN) has guidelines for sentinel lymph node biopsy (SLNB) which recommend "discuss and consider" SLNB for invasion >0.75 mm and "discuss and offer" SLNB for invasion >0.75 mm with suspicious features. This study looked at compliance with NCCN guidelines and factors that are predictive of a positive SLNB. This is a retrospective study of patients diagnosed with thin melanoma 2012-2013 using the National Cancer Database. A total of 26,456 patients met study qualifications. Univariate analysis showed that 76 per cent of patients meeting criteria underwent SLNB. Patients recommended to "discuss and consider" received SLNB 53 per cent of the time and those not recommended for SLNB received SLNB 20 per cent of the time. On multivariate analysis, depth was not predictive for positive SLNB whereas mitoses and ulceration were. Other factors predictive of positive SLNB were nodular cell type, lymphovascular invasion, and Clark's level greater than or equal to IV. Patients with thin melanoma that meet NCCN guidelines for SLNB undergo this procedure in good compliance but those who do not meet criteria continue to receive SLNB. Positive predictive factors for positive SLNB include mitoses, ulceration, Clark's level, and primary site.

Entities:  

Mesh:

Year:  2018        PMID: 29966567

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

Review 1.  Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies.

Authors:  Mariana B Sadurní; Alexander Meves
Journal:  Mod Pathol       Date:  2022-06-02       Impact factor: 8.209

2.  Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.

Authors:  Domenico Bellomo; Suzette M Arias-Mejias; Chandru Ramana; Joel B Heim; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Mark R Pittelkow; David J DiCaudo; Barbara A Pockaj; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves
Journal:  JCO Precis Oncol       Date:  2020-04-14

3.  Population-based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma.

Authors:  Sita Ollek; Stephanie Minkova; Kadhim Taqi; Leo Chen; Magdalena Martinka; Noelle Davis; Trevor Hamilton; Heather Stuart
Journal:  Can J Surg       Date:  2022-06-14       Impact factor: 2.840

4.  Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Authors:  E E A P Mulder; J T Dwarkasing; D Tempel; A van der Spek; L Bosman; D Verver; A L Mooyaart; A A M van der Veldt; C Verhoef; T E C Nijsten; D J Grunhagen; L M Hollestein
Journal:  Br J Dermatol       Date:  2020-11-02       Impact factor: 9.302

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.